RIP kinase

Cat.No. Product Name Information Product Use Citations Product Validations
S8037 Necrostatin-1 (Nec-1) Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Cell Res, 2025, 10.1038/s41422-025-01167-8
Signal Transduct Target Ther, 2025, 10(1):341
Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1317
Verified customer review of Necrostatin-1 (Nec-1)
S8641 Necrostatin 2 racemate (Nec-1s) Necrostatin 2 racemate (Nec-1s, 7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S) is a stable variant of Necrostatin-1. This compound is a more specific RIPK1 inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases.
Nature, 2025, 10.1038/s41586-025-09741-1
Cell, 2025, S0092-8674(25)01233-4
Cancer Cell, 2025, S1535-6108(25)00132-1
S8465 GSK872 GSK'872 is a potent and selective RIP3 kinase inhibitor which binds RIP3 kinase domain with high affinity (IC50=1.8 nM) and inhibits kinase activity with IC50 of 1.3 nM. It has minimal cross-reactivity.
Nature, 2025, 647(8090):735-746
Nature, 2025, 10.1038/s41586-025-09741-1
Cell Res, 2025, 10.1038/s41422-025-01167-8
Verified customer review of GSK872
S9733 Mito-TEMPO Mito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
Clin Transl Med, 2025, 15(1):e70180
J Biol Chem, 2025, 301(10):110653
Nat Commun, 2024, 15(1):1669
S8642 GSK'963 GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10 000-fold selective for RIP1 over 339 other kinases.
PLoS Biol, 2025, 23(2):e3002845
Cell Death Discov, 2024, 10(1):122
Sci Rep, 2024, 14(1):4409
S6511 RIPA-56 RIPA-56 is a highly-potent, selective, and metabolically stable RIP1 (RIPK1) inhibitor.
Cell Genom, 2024, 4(2):100487
Ann Transl Med, 2022, 10(22):1245
J Oncol, 2022, 2022:2390078
S8484 GSK2982772 GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. It has exquisite kinase specificity and excellent activity in blocking many TNF-dependent cellular responses.
Antioxidants (Basel), 2021, 10(9)1347
Mol Cell Biochem, 2021, 10.1007/s11010-021-04136-y
Exp Ther Med, 2021, 21(2):163
S3238 Resibufogenin Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. This compound exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. It induces apoptosis and caspase-3 and caspase-8 activity. This chemical increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
bioRxiv, 2025, 2025.07.17.665404
Research Square, 2024, 10.21203/rs.3.rs-3790060/v1
Phytomedicine, 2022, 102:154182
S8261 GSK583 GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. This compound also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures.
J Invest Dermatol, 2025, S0022-202X(25)00494-4
Cancer Res, 2020, canres.530.2020
J Neuroinflammation, 2020, 17(1):364
S8775 HS-1371 HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.
Nature, 2024, 625(7995):585-592
Oncogene, 2021, 10.1038/s41388-021-01869-4
Int J Mol Sci, 2021, 22(15)7983